- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02307721
Pharmacokinetics and Pharmacodynamics of a New Formulation of Nasal Naloxone for Prehospital Use (OPI-14-001)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Healthy volunteers will be brought into a state of opioid influence in a well-known, short acting, controlled and safe manner using remifentanil.
Naloxone is a well-known, well-tolerated drug with an excellent safety profile over many decades of use. The current formulation has proven safe and without local or systemic side effects in the studies conducted so far. The excipients in the present nasal formulation are all well known.
This study has two aims. Firstly to investigate what naloxone does to the body under opioid influence, applying a well-tested model with infusion of the potent opioid remifentanil (Target Control Infusion). This will create a state of strong opioid effect for a short time and in a highly controlled fashion, inducing a state of miosis, reduced respiratory rate and reduced sensation to pain, all three strong indicators of opiates. Naloxone will antagonise these effects, and this change can be measured. Choosing intramuscular 0.8 mg naloxone for comparison means that the novel intranasal naloxone formulation will be compared with the well-established and described treatment protocol for opioid overdose in Norway used today.
Secondly the pharmacokinetic profile of intranasal and intramuscular naloxone will be studied. The same measurements as in preparative studies (OPI 12-001 and OPI 13-001) will be taken: Serum naloxone concentration over time to calculate maximum concentration, Time to maximum concentration, Area Under the Curve and Relative bioavailability. There are two main reasons to repeat these measurements. In contrast to the previous studies under the current protocol the participants will be under the influence by strong opioids. This may have significant physiologic effects, and it will be explored whether the pharmacokinetics of the intranasal formulation are changed. The other reason is that in this study pharmacokinetics of naloxone will be compared with the actual dosage and administration routes of naloxone as used by doctors and paramedics in the pre-hospital setting. This has not been done before, in spite of the widespread use of this treatment, The measurements of remifentanil in serum open the possibility to relate pharmacodynamic data directly to an actual serum concentration of the opioid at the same time.
Care will be taken not to include opioid users in this study as naloxone would precipitate acute withdrawal. Also possible drug misusers will be excluded as well as people who have access to remifentanil and infusion equipment in their daily work, although the abuse potential of this highly specialised drug is minimal.
Safety of the formulation will also be studied by measuring vital signs and for the patient to report any nasal discomfort or potential adverse reactions during the study.
By weighing spray device, and intramuscular syringes before and after discharge the reliability of the dose delivered will be confirmed.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Trondheim, Norway
- Department of Circulation and Medical Imaging
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- American Society of Anesthesiologists (ASA) class I
- ECG without pathologic abnormalities
- BMI range of 18,5 - 24,9 kg/m2.
lab values within reference values at St Olav's Hospital for the relevant haematological and biochemical test for inclusion:
- Haemoglobin (male: 13.4-17.0 g/dL, female 11.7 - 15.3 g/dL)
- Creatinine (male: 60-105 micromole/L, female 45 - 90 micromole/L)
- Aspartate aminotransferases (ASAT) (male: 15-45 U/L, female: 15-35 U/L)
- Alanine transaminase (ALAT) (male: 10-70 U/L, female: 10-45 U/L)
- Gamma glutamyl transpeptidase (GT) (male: 10-80 U/L, female: 10-45 U/L)
- For women in reproductive age: serum HCG (normal under 3 ye/L)
- Signed informed consent and expected cooperation of the subjects for the treatment
Exclusion Criteria:
- Taking any medications including herbal medicines the last week prior to treatment visits
- Current or history of drug and/or alcohol abuse (To assess problematic drug or alcohol use we use the CAGE AID screening tool)
- History of contact with police or authorities in relation to alcohol or drug offences
- History of prolonged use of opioid analgesics
- History of prior drug allergy
- Having any local nasal disease or nasal surgery for the last 2 months or recent cold for the last week
- Pregnant women (HCG over 3 ye/L at inclusion)
- Women in reproductive age not using high efficacy contraceptives (Oral contraceptives, Patch (Evra), Implants, Vaginal ring, Hormonal IUD, Copper intra-uterine device (IUD), Sterilization) throughout the study period until their last visit.
- Breastfeeding women
- Participants with access to remifentanil or other potent opioids in their daily workplace.
- Hypersensitivity to naloxone or remifentanil hydrochloride and/or to any of its excipients.
- Any reason why, in the opinion of the investigator, the patient should not participate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: intranasal naloxone
8 mg/ml naloxone 0,1 mL IN as one puff in one nostril in supine position
|
Administer 0,1 ml 8 mg/ml naloxone intranasally, dose = 0,8 mg naloxone
Administer remifentanil intravenously by way of Target Control Infusion, Minto model at a target of 2,5 ng/ml.
This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone.
After treatment of 4 participants protocol amended 22. january 2015 to reduce remifentanil target to 1,25 ng/ml in the next 4.
In the last 4 participants the dose will be decided later, but not exceed 2,5 ng/ml.
This is the spray device chosen, and its function in this setting (spray up side down) will be assessed by weighing the device before and after administration.
|
Active Comparator: Intramuscular naloxone
0,4 mg/ml Naloxone B Braun 2 ML in deltoid muscle
|
Administer remifentanil intravenously by way of Target Control Infusion, Minto model at a target of 2,5 ng/ml.
This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone.
After treatment of 4 participants protocol amended 22. january 2015 to reduce remifentanil target to 1,25 ng/ml in the next 4.
In the last 4 participants the dose will be decided later, but not exceed 2,5 ng/ml.
Administer 2 mL, dose intramuscular naloxone 0,8 mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacodynamic profile of naloxone- Heat Pain Threshold
Time Frame: 120 minutes
|
We will measure time to maximum reversal, and duration of reversal of opioid effect on heat pain threshold measured.
Heat pain thresholds will be tested using a Somedic MSA Thermotest (Somedic AB, Hørby, Sweden).
This apparatus can measure the relationship between the intensity of controlled thermal stimuli and the associated perception.
The stimulus (1 degree Celsius per sec rise time) is applied to the intact skin by a hand-held thermode while monitoring the temperature.
The thermode (area 25x 50 mm= 12,5 cm2) will be placed over the non-dominant thenar eminence.
Once the sensation changes from warm to painful the subject stops the increase in temperature by pressing a button, and the thermode cools down.
The heat pain threshold (HPT) is measured in degrees C, and we will calculate the average of three repeated single HPTs.
|
120 minutes
|
Pharmacodynamic profile of naloxone. Pupillometry
Time Frame: 120 minutes
|
Using a Neuroptics VIP 200 Pupillometer (Neuroptics, Irvine, CA, USA) we will measure the size of the pupils as a pharmacodynamic measure.
The treatment visits will be conducted in a quiet room, with moderate, stable ambient lighting.
Using a luxometer we will ensure similar light conditions in each visit of each participant.
We will ask the participant to focus on a distant point in the room.
The pupillometer will be placed over the measured eye and its position adjusted until the eye was correctly aligned within the LCD screen of the pupillometer.
The reading will be recorded in CRF and/ or local work sheet A measurement of the pupils should take less than 10 seconds, and the result is given in millimetre, with an accuracy of 0.1mm and the results recorded.
It is a non-invasive and pain free measurement.
|
120 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: minimum 6 days
|
will be reported from the start of the first session to the follow-up visit.
|
minimum 6 days
|
Quantitate serum concentrations of remifentanil at specified time points
Time Frame: 110 minutes
|
Measure serum concentration of remifentanil by Gas Chromatography-Mass Spectrometry (GCMS) at 0,15,30,45, 60 and 90 minutes.
|
110 minutes
|
Suitability of spray device in prehospital setting
Time Frame: 100 minutes
|
By weighting spray device before and after intranasal administration to asses function in the supine patient.
|
100 minutes
|
Pharmacokinetics: Area Under the Curve of IN and IM naloxone
Time Frame: 360 minutes
|
Measurement of serum naloxone at times 2,5,10,15,20,25,30,35,45,60,90,120,240 and 360 minutes after naloxone administration
|
360 minutes
|
Pharmacokinetics: maximum concentration (Cmax) of IN and IM naloxone
Time Frame: 360 minutes
|
Measurement of serum naloxone at times 2, 5, 10, 15, 20, 25, 30, 35, 45, 60, 90, 120, 240 and 360 minutes after naloxone administration
|
360 minutes
|
Pharmacokinetics: time to maximum concentration (Tmax) of IN and IM naloxone
Time Frame: 360 minutes
|
Measurement of serum naloxone at times 2, 5, 10, 15, 20, 25, 30, 35, 45, 60, 90, 120, 240 and 360 minutes after naloxone administration
|
360 minutes
|
Collaborators and Investigators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OPI-14-001
- 2014-001465-27 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Overdose
-
NHS Greater Glasgow and ClydePublic Health ScotlandRecruitingDrug Effect | Drug Use | Drug Abuse | Drug Toxicity | Illicit Drug Use | Overdose, Drug | Illicit Drug Overdose | Illicit Drug IntoxicationUnited Kingdom
-
Oregon Health and Science UniversityOregon State University; Oregon Department of Corrections; CODA Inc.; Bridgeway... and other collaboratorsCompleted
-
Emergent BioSolutionsCompletedOpioid OverdoseUnited States
-
University Hospital Bispebjerg and FrederiksbergCompletedDrug Overdose | Overdose of Beta-adrenergic Blocking DrugDenmark
-
San Francisco Department of Public HealthCompletedOpioid-Related Disorders | Drug OverdoseUnited States
-
San Francisco Department of Public HealthRecruitingStimulant Overdose | Overdose Accidental | Overdose Cocaine | Overdose MethamphetamineUnited States
-
University of CincinnatiNational Institute on Drug Abuse (NIDA)CompletedOpioid-Related Disorders | Substance Abuse | Drug Overdose | Drug Abuse | Drug AddictionUnited States
-
Mikkel Bring ChristensenCompletedBlood Pressure | Drug Overdose | Overdose of Beta-adrenergic Blocking DrugDenmark
-
Nationwide Children's HospitalRecruitingHarm Reduction | Opiate Overdose | Fentanyl OverdoseUnited States
-
Nationwide Children's HospitalRecruitingHarm Reduction | Opiate Overdose | Fentanyl OverdoseUnited States
Clinical Trials on Intranasal naloxone
-
Norwegian University of Science and TechnologyOslo University Hospital; St. Olavs HospitalCompletedOverdose | Drug AbuseNorway
-
Norwegian University of Science and TechnologySt. Olavs Hospital; Smerud Medical Research International AS; A/S Den norske...Completed
-
Norwegian University of Science and TechnologySt. Olavs Hospital; University of IcelandCompleted
-
Parc de Salut MarFood and Drug Administration (FDA)Recruiting
-
Leiden University Medical CenterU.S. Food and Drug Administration (FDA)RecruitingChronic Opioid Use | Opioid Induced Respiratory DepressionNetherlands
-
Isfahan University of Medical SciencesCompletedMorphinan Opioid OverdoseIran, Islamic Republic of
-
University of Maryland, BaltimoreRecruitingPain | Virtual Reality | PlaceboUnited States
-
Intersect ENTCompleted
-
Bastyr UniversityNational Center for Complementary and Integrative Health (NCCIH)Completed